DeepCure Inc.

1:45 PM - 2:00 PM (EDT), Monday, June 5, 2023 ・ Session Room 104A
DeepCure is building a different kind of AI biotech company. DeepCure’s AI is harnessing the power of a molecular foundry to synthesize and assay compounds from the world’s largest small molecule library.

DeepCure is a biotech company with preclinical immunology and oncology assets looking for partners to collaborate on current and new small molecule discovery programs.

Deepcure is building a platform that focuses on what drug hunters need. The platform leverages AI to predict binding, selectivity, and other pharmacological properties for optimization, an ultra-large chemical library (10^18 compounds), and a molecular foundry to automate synthesis and assays.

DeepCure was founded at the Massachusetts Institute of Technology (MIT) to accelerate breakthroughs in drug discovery and has raised $47 million from investors, including Morningside. DeepCure is a world-class team of drug discovery and computer scientists headquartered in Boston, MA.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
Anti-inflammatory, Anti-fibrotic
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Chief Business Officer